New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
18:58 EDTCLDX, SIMO, YUM, OGXI, HOLX, THO, IDIX, BIDUOn The Fly: After Hours Movers
UP AFTER PRELIMINARY EARNINGS: Thor Industries (THO), up 3.7% after preliminary Q2 revenue beats estimates... DOWN AFTER EARNINGS: Yum! Brands (YUM), down 5.4% after cutting its FY13 EPS view, reporting Q4 China SSS down 6%... Baidu (BIDU), down 5.2%... Hologic (HOLX), down 4.1%... Silicon Motion (SIMO), down 10.9% after reporting Q4 earnings and saying it sees Q1 revenue own 15%-25% sequentially... ALSO LOWER: Idenix (IDIX), down 5.9% after announcing it had discontinued clinical development for a hepatitis C treatment... OncoGenex (OGXI), down 3.3% after disclosing the resignation of its CFO... Celldex (CLDX), down 3.3% after filing to sell $75M in common stock.
News For THO;YUM;BIDU;HOLX;SIMO;IDIX;OGXI;CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 24, 2015
07:15 EDTCLDXCelldex reports Q4 EPS (36c), consensus (35c)
Subscribe for More Information
February 23, 2015
10:36 EDTBIDUBaidu calls active amid renewed takeover speculation
Baidu February weekly 210 and 212 calls are active on total call volume of 7K (1K puts) amid renewed takeover speculation. February weekly call option implied volatility is at 29, March is at 26, April is at 27; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:31 EDTBIDURumor: Baidu moves higher amid renewed takeover speculation
Subscribe for More Information
09:25 EDTCLDXOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTCLDXCelldex rindopepimut receives FDA breakthrough therapy designation
Celldex Therapeutics announced that the FDA has granted rindopepimut Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma, or GBM. This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. An international Phase 3 study of rindopepimut, called ACT IV, in newly diagnosed GBM completed enrollment in December of 2014.
February 19, 2015
09:59 EDTHOLXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
07:28 EDTHOLXHologic upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:35 EDTHOLXHologic upgraded to Buy from Hold at Canaccord
February 18, 2015
11:50 EDTSIMOSilicon Motion management to meet with Needham
Subscribe for More Information
February 17, 2015
09:40 EDTBIDUActive equity options trading on open
Subscribe for More Information
February 13, 2015
17:40 EDTHOLXRelational Investors gives quarterly update on stakes
Subscribe for More Information
February 12, 2015
10:00 EDTBIDUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTBIDUActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA WFM BIDU TWTR GILD FB AMAT EXPE TRIP
09:22 EDTBIDUOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tripadvisor (TRIP), up 13.5%... Cisco Systems (CSCO), up 7.2%... FireEye (FEYE), up 7.7%... GNC (GNC), up 4.8%... NVIDIA (NVDA), up 5.5%... Whole Foods (WFM), up 2.5%. ALSO HIGHER: Orbitz Worldwide (OWW), up 21.6% after agreeing to be acquired by Expedia (EXPE). Expedia is up 11%... Ballard Power (BLDP), up 8.1% after being upgraded to Buy from Hold at Lake Street... Verastem (VSTM), up 4.7% after receiving orphan drug designation from FDA VS-5584 in mesothelioma. DOWN AFTER EARNINGS: Zulily (ZU), down 25.4%... Cabelas (CAB), down 9%... Cheesecake Factory (CAKE), down 5.9%.... Baidu (BIDU), down 4.8%... NetApp (NTAP), down 6.5%... Avon Products (AVP), down 3.6%... Tesla (TSLA), down 8.9%... Kellogg (K), down 5.1%... Amber Road (AMBR), down 16%. ALSO LOWER: Achillion Pharmaceuticals (ACHN), down 4.5% after 12M share Secondary priced at $10.25.
07:51 EDTBIDUBaidu price target lowered to $230 from $280 at Oppenheimer
Oppenheimer lowered its price target for Baidu shares to $230 saying "aggressive" promotional spending relating to mobile products drove the "soft" margin outlook. The firm notes management expects growth to pick up starting in Q2. It keeps an Outperform rating on Baidu.
07:43 EDTBIDUBaidu price target lowered to $250 from $275 at Brean Capital
Subscribe for More Information
07:36 EDTBIDUBaidu downgraded at Stifel
Subscribe for More Information
07:23 EDTBIDUBaidu price target lowered to $253 from $283 at Jefferies
Jefferies lowered its price target for Baidu shares to $253 after the company's Q1 revenue outlook missed expectations. The firm sees the near-term correction in shares as a buying opportunity as it expects results to rebound in Q2. Jefferies keeps a Buy rating on the stock.
07:19 EDTBIDUBaidu subsidiary granted exclusive rights from CCTV
Subscribe for More Information
06:52 EDTBIDUBaidu downgraded to Hold from Buy at Stifel
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use